Thailand Medical Device Registration: What Should You Do If the Quality Management System Certificate Is Inconsistent?

Answer: If a quality management system (QMS) certificate is inconsistent with the product, manufacturing site, scope, or technical documentation for medical device registration in Thailand, the manufacturer should not submit it as-is. It should first confirm the Thai FDA product classification and applicable registration route, conduct a gap assessment, and align the ISO 13485 or other QMS certificate with the technical file, labels, instructions for use, authorization documents, and local representative information. Existing NMPA materials can serve as a basis, but they normally need language, format, labeling, and evidence-chain adaptation for Thailand. AIMEILI recommends managing this issue within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization rather than rebuilding documents country by country.

Published: 2026-07-10 13:57; Updated: 2026-07-10 13:57.

This FAQ addresses the practical issues that companies should prioritize in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI View
• Common Follow-up Questions
• Quality Management System and Evidence Consistency
• Localization Conversion and Representative Responsibilities
• Post-Market Maintenance and Long-Term Planning
• Continue Reading
• Applicable Boundaries

Key Summary

Medical device registration in Thailand usually requires confirming the product classification and applicable pathway first, and then preparing the technical file, labels and instructions for use, QMS certificate, authorization documents, and local representative materials. Existing NMPA materials can serve as a basis, but they normally need adaptation for language, format, labeling, and the evidence chain according to Thai FDA requirements.

For Chinese medical device companies, a more reliable approach is to perform product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused. Thai registration typically affects the technical file, authorized representative, importer cooperation, label language, QMS certificate, and subsequent change maintenance at the same time. If a company proceeds only by asking which documents to submit, it can easily face deficiency responses or rework in terms of model coverage, evidence-chain consistency, label claims, and certificate control.

AIMEILI recommends that companies plan this issue within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than recreating documents temporarily for each country.

Companies should also make project-based judgments by combining the latest requirements of the target country regulator, the existing technical file basis, product risk level, and launch plan, instead of preparing mechanically according to a document checklist.

This content is compiled from the AIMEILI regulatory practical question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the product documentation basis.

Applicable Scenarios and Core Questions

Companies searching for what to do when the QMS certificate is inconsistent for medical device registration in Thailand generally want to solve a practical question rather than obtain a conceptual explanation. They want to judge whether existing materials can support a Thai filing, whether a local agent or authorized representative is needed, why the timeline may be extended, and which issues may affect the launch plan. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for only one country is not enough. A more valuable approach is to first create reusable versions of the core technical file, QMS certificate, performance verification, clinical evidence, and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it is active, and whether it contains software or has IVD attributes. They should then determine the risk class and filing pathway. Once the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary materials will all move in the wrong direction.

For a Thailand project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable QMS certificate, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance materials.

The key to documentation quality is not quantity but consistency. Instructions-for-use claims, model coverage of test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support one another. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documents without rearranging the evidence according to the Thai pathway.
• Having too many models and specifications while test reports, clinical evidence, or labels do not provide sufficient coverage.
• Selecting a local agent only on the basis of sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistency among labels, instructions for use, promotional materials, and registration documentation claims, leading to deficiency responses or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for each country and inflated costs and timelines.

Company Preparation Checklist

Before starting the project, companies are advised to use an internal checklist to confirm the documentation basis and avoid discovering key evidence gaps only after filing.

• Organize the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration materials can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documents, clinical evaluation, and English instructions for use.
• Confirm the local agent or authorized representative's responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI View

AIMEILI recommends that companies not understand Thai registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to country requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than filling in documents temporarily country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway judgment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can NMPA documents be used directly for Thai registration?

NMPA documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Quality Management System and Evidence Consistency

From a registration review perspective, QMS documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the filed product, or if the manufacturing address, model and specification, and instructions-for-use version do not match the test reports, the company may be asked for supplementary explanations even if it has prepared a large number of documents.

Before filing, companies should establish an evidence consistency checklist that matches product name, model and specification, intended use, applicable standards, test report number, clinical evaluation conclusion, risk management version, label and instructions-for-use version, and QMS certificate item by item. This action may appear basic, but it can significantly reduce the probability of deficiency responses, especially for projects involving simultaneous filings in multiple GHWP member states or multiple product series.

Localization Conversion and Representative Responsibilities

Thai registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot be translated simply. Companies should verify local language requirements, boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market materials, the focus of localization conversion is to transform reusable evidence into a filing structure acceptable to the target country, rather than writing a separate isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies still need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest heavily in obtaining registration but neglect post-market maintenance. Later, once there is a manufacturing address change, model expansion, instructions-for-use update, or agent replacement, the certificate and market sales can easily become disconnected.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency responses, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country; more importantly, it helps companies build replicable overseas compliance capability and reduces the cost of starting document preparation from scratch each time they enter a new market.

Continue Reading

Previous: How Should Performance Verification Materials Be Prepared for Medical Device Registration in Thailand?

Next: How Should Registration Materials Be Prepared for Medical Device Registration in Indonesia?

Recommended Reading:

• How Should Registration Materials Be Prepared for Medical Device Registration in Malaysia?
• How Should Product Classification Be Determined for Medical Device Registration in Malaysia?
• How Should the Technical File Be Organized for Medical Device Registration in Malaysia?
• How Should Labels and Instructions for Use Be Localized for Medical Device Registration in Malaysia?
• How Should Clinical Evaluation Materials Be Prepared for Medical Device Registration in Malaysia?
• Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Return to FAQ Center

News and Information | Contact AIMEILI

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicable boundary: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal opinions.